dafa登录官网|欢迎莅临!

Reliable Quality

Affordable Innovation

Name Indication Clinical Trial Phase Study Title
HLX60
Solid Tumors and Lymphoma
Phase I A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
HLX53
Solid Tumors or Lymphoma
Phase I A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma
HLX10+HLX208
NSCLC With BRAF V600E Mutation
I b/Phase Ⅱ A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
HLX10+HLX26
Solid Tumours
Phase I A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 Monoclonal Antibody Injection in Combination With HLX10 Monoclonal Antibody Injection in Patients With Advanced/Metastatic Solid Tumor
HLX10+HLX07
Squamous Non-small-cell Lung Cancer
Phase III A Randomized, Open-Label, Multicenter, Phase II Study of HLX07 (Anti-EGFR Antibody) +HLX10 (Anti-PD-1 Antibody) With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
XML 地图 | Sitemap 地图